EDGAR·FLOW

Immix Biopharma, Inc. — Form 8-K

Filed September 30, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Immix Biopharma priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share on September 29, 2026, generating gross proceeds of approximately $125 million. J.P. Morgan Securities LLC acted as sole book-running manager. The company intends to use net proceeds for NXC-201 development, working capital, and general corporate purposes. Closing was expected September 30, 2026.
Why this rating

Substantial capital raise (~$125M gross) represents ~3.5x company's $35.7M market cap—material liquidity infusion for clinical-stage biotech. Positive for runway and development.

Tradability signal
NO TRADE

No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=139). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$10.40 ▼ 0.05%
at our read · unknown
$10.40
+10 min · unknown
$10.18 ▼ 2.16%
+30 min · unknown
$10.09 ▼ 3.08%
+1 hr · unknown
$9.92 ▼ 4.66%
+4 hrs · unknown
$10.44 ▲ 0.34%

The stock had already moved +0.05% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ IMMX · stock on Yahoo Finance ↗

See more from September 30, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.